HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
15.04
-0.21 (-1.38%)
At close: Mar 31, 2025, 4:00 PM
15.08
+0.04 (0.26%)
After-hours: Mar 31, 2025, 4:09 PM EDT
HUTCHMED (China) Revenue
In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%. HUTCHMED (China) had revenue of $324.52M in the half year ending December 31, 2024, with 44.64% growth.
Revenue (ttm)
$630.20M
Revenue Growth
-24.80%
P/S Ratio
4.07
Revenue / Employee
$347,985
Employees
1,811
Market Cap
2.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
HCM News
- 10 days ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire
- 11 days ago - Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewsWire
- 11 days ago - HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewsWire
- 12 days ago - HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength - Benzinga
- 12 days ago - HUTCHMED Reports 2024 Full Year Results and Provides Business Updates - GlobeNewsWire
- 12 days ago - HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China - GlobeNewsWire
- 25 days ago - HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China - GlobeNewsWire